Is adalimumab protective in ischemia-reperfusion injury in lung?

Kurt A., TUMKAYA L., Kalkan Y., TÜRÜT H., CURE M. C., CURE E., ...Daha Fazla

IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, cilt.18, sa.11, ss.1093-1099, 2015 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 11
  • Basım Tarihi: 2015
  • Dergi Adı: IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1093-1099
  • Anahtar Kelimeler: Adalimumab, Endothelin-1, Ischemia reperfusion, Lung injury, Tumor necrosis factor-alpha, RHEUMATOID-ARTHRITIS, ENDOTHELIN-1, MALONDIALDEHYDE, INFLIXIMAB, APOPTOSIS, SAFETY
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Evet

Özet

Objective(s): Increasing cytokines and reactive oxygen species (ROS) during ischemia reperfusion (I-R) leads to the lung damage. Adalimumab (Ada) is a potent tumor necrosis factor-alpha (TNF-alpha) inhibitor agent. We aimed to evaluate whether Ada would prevent the lung tissue from damage development over the I-R process.